Open Account
العربية
Open Account

Novartis Announced Earlier, Continuous Kesimpta Treatment For Up To Six Years Showed Sustained Efficacy In Recently Diagnosed (≤3 Years) Treatment-naïve People Living With Relapsing Multiple Sclerosis In Analysis Of Alithios Open-label Extension S...

Novartis AG Sponsored ADR +1.09% Pre

Novartis AG Sponsored ADR

NVS

0.00

  • Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1
     
  • Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2
     
  • Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy outcomes such as annualized relapse rate and MRI lesion activity in both analyses1,2
     
  • Treatment with Kesimpta for up to six years continues to be well tolerated with consistent safety outcomes, supporting the favorable benefit-risk profile of Kesimpta in RMS2
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via